Pages that link to "Q30488298"

The following pages link to Activation of dopamine D1 receptors blocks phencyclidine-induced neurotoxicity by enhancing N-methyl-D-aspartate receptor-mediated synaptic strength (Q30488298):

Displaying 13 items.

• Synapse-specific contributions in the cortical pathology of schizophrenia (Q26825577) (← links)
• Anatomical transcriptome of G protein-coupled receptors leads to the identification of a novel therapeutic candidate GPR52 for psychiatric disorders (Q28506753) (← links)
• Effects of the D1 Dopamine Receptor Agonist Dihydrexidine (DAR-0100A) on Working Memory in Schizotypal Personality Disorder (Q29038503) (← links)
• Models of neurodevelopmental abnormalities in schizophrenia (Q30457462) (← links)
• Animal models of schizophrenia. (Q30462828) (← links)
• Effects of chronic oral treatment with aripiprazole on the expression of NMDA receptor subunits and binding sites in rat brain (Q34628396) (← links)
• Investigational drugs for schizophrenia targeting the dopamine receptor: phase II trials (Q34703195) (← links)
• Emerging drugs for schizophrenia (Q37874626) (← links)
• Antipsychotic treatment modulates glutamate transport and NMDA receptor expression (Q38248566) (← links)
• The Regulation of GluN2A by Endogenous and Exogenous Regulators in the Central Nervous System (Q38852012) (← links)
• Metaplasticity gated through differential regulation of GluN2A versus GluN2B receptors by Src family kinases (Q41165539) (← links)
• α-amino-3-hydroxy-5-methyl-4-isoxazoleproprionic acid receptor activation protects against phencyclidine-induced caspase-3 activity by activating voltage-gated calcium channels (Q42670341) (← links)
• Re-exposure to morphine-associated context facilitated long-term potentiation in the vSUB-NAc glutamatergic pathway via GluN2B-containing receptor activation (Q49116848) (← links)